Roche has revealed new phase 2 data with enicepatide (formerly CT-388), its potential rival to Eli Lilly's dual GIP/GLP-1 ...

The Swiss pharma group has just reported topline results from the phase 3 IMAgINATION study of Factor B inhibitor sefaxersen ...

Dazodalibep is one of the assets included in Amgen's near-$28 billion takeover of Horizon Pharma in 2023, which also gave it ...

The UK's National Institute for Health and Care Research (NIHR) has revealed the first round of funding for an initiative that aims to bridge the gap between early-stage medical discoveries and ...

Citing former Italian prime Minister and economist Mario Draghi, the company leaders have urged the EU and national governments in Europe to counter the 'slow agony' of decline facing strategic ...

Everyone agrees that AI is changing pharmacovigilance. But the nature of that change is evolving. The first wave of AI deployment in pharmacovigilance focused on automating repetitive tasks, but the ...

Earlier this year, the FDA released draft guidance endorsing Bayesian methods and simulation-based evidence in clinical ...

Adding ITM will also give Telix a pipeline of follow-up radiopharma candidates, including clinical-stage diagnostics and ...

Iambic Therapeutics, which specialises in applying AI to drug discovery and development, has filed for an IPO on the Nasdaq, shortly after adding AbbVie to its roster of pharma pa ...

The FDA has published the design of its expedited Investigational New Drug (IND) pilot, part of a plan to restore US competitiveness in clinical research, and will now accept applications to take part ...

Around 1,000 patients in England with a form of incurable breast cancer will be able to get access to AstraZeneca and Daiichi Sankyo's life-extending drug, Enhertu, via the NHS from today. Final draft ...

Avalere Health was the most successful agency, winning three Golds, a Silver and the highly contested accolade of PMi Agency ...